By Denny Jacob
Medtronic said the Food and Drug Administration approved a brain stimulation system for people afflicted with Parkinson's disease.
The medical technology company said the regulator approved BrainSense Adaptive deep brain stimulation and BrainSense Electrode Identifier. It added that they offer therapy personalization for symptom control that automatically adjusts to a patient's needs.
Medtronic said both BrainSense offerings are available in Europe. Patient programmings in the U.S. will begin at select healthcare systems over the coming weeks with availability nationwide in the coming months, it added.
Parkinson's occurs when cells deep in the brain that produce dopamine, which coordinates movement, become impaired or die. Symptoms include tremors, stiffness, slow movements and problems with balance.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 24, 2025 09:28 ET (14:28 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.